European Healthcare Sector Launches Major Initiative to Eliminate Toxic Chemicals
Wageningen, Thursday, 15 October 2026.
The newly launched PFAROS consortium unites 89 European partners to eliminate toxic forever chemicals from healthcare supply chains, driving sustainable medical innovation and reducing environmental contamination by 2050.
Addressing Forever Chemicals in Healthtech and Pharmaceuticals
The initiative sits at the intersection of healthtech and pharmaceuticals, targeting the systemic reliance on per- and poly-fluoroalkyl substances (PFAS) across medical equipment, drug packaging, and facility operations [1][2]. Commonly known as ‘forever chemicals’ due to their persistent carbon-fluorine bonds, synthetic PFAS compounds present severe environmental and human health risks [2][5]. To mitigate these hazards without compromising patient safety, the newly launched PFAROS consortium—funded under the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 10125128 1—has initiated a five-year research program running from 2026 to 2031 [1][4]. The project aims to phase out harmful PFAS substances completely across European healthcare supply chains by 2050 [2].
Consortium Leadership and Cross-Sector Collaboration
The initiative is led by project coordinator Ghent University, based in Ghent, Belgium, alongside industry lead UCB and project co-lead Biotronik [2][3]. The collaborative network spans 89 partners, incorporating research institutions, industrial leaders, regulators, and non-governmental organizations like Health Care Without Harm (HCWH) Europe [1][3]. Individual academic and industry leaders play defined roles: Kevin Van Geem serves as the project coordinator at Ghent University, John O’Hara leads the industry arm for UCB, Maricica Munteanu-Kempa acts as project co-lead for Biotronik, and project leader Rian Ruhl manages research activities at Wageningen University & Research (WUR) [1][2]. Additionally, institutions like Sweden’s RISE research institute, represented by Karin Persson at the project’s Ghent kick-off meeting, contribute technical expertise to develop non-toxic alternatives [3][4].
How the Safe and Sustainable by Design Framework Works
PFAROS operates using the European Commission’s Safe and Sustainable by Design (SSbD) framework, focusing on replacing PFAS in medical devices, active pharmaceutical ingredients, packaging, and facility cleaning agents [1][2][4]. At Wageningen University & Research in the Netherlands, researchers combine toxicological analysis from Wageningen Food Safety Research with material science and water treatment expertise from Wageningen Food & Biobased Research [1][6]. On a laboratory scale, researchers evaluate potential chemical substitutes for performance, end-of-life environmental impact, and broader sustainability metrics, while simultaneously testing advanced purification techniques to remove residual PFAS from hospital and manufacturing wastewater [1][6]. To streamline adoption, the consortium is developing an AI-powered data tool to accelerate the assessment of substitute materials and formulate a European roadmap for emission reduction [2].
Regulatory Drivers and Long-Term Strategic Benefits
The push to eliminate PFAS from healthcare coincides with tightening regulatory standards across Europe, including mandatory drinking water monitoring established in January 2026 and restrictions on food-contact packaging enforced on August 12, 2026 [5]. Furthermore, the European Chemicals Agency (ECHA) scientific committees backed a class-wide restriction on approximately 14,000 PFAS compounds in March 2026, creating potential market impacts for medical technology by 2029 [5]. By establishing plug-and-play, science-based alternatives, the PFAROS project secures the long-term resilience of European healthtech and pharmaceutical sectors while creating commercial opportunities in sustainable life sciences [2][3]. Ultimately, eliminating hazardous chemicals from medical products ensures that healthcare facilities do not inadvertently contribute to global pollution while delivering essential care [3].